why is OKYO "Consensus Rating "Strong Buy""

The consensus rating for OKYO Pharma (NASDAQ:OKYO) is "Strong Buy" based on the following points:

1. **Potential Upside**: OKYO Pharma has a consensus target price of $7.00, indicating a potential upside of 430.30%. This high probable upside, according to analysts, is a strong indicator of a "Strong Buy" rating.
2. **Recent Developments**: OKYO Pharma has recently secured a key U.S. patent for its dry eye disease therapy, which could be a catalyst for the stock's potential growth. This kind of development can boost investor confidence and contribute to a "Strong Buy" rating.
3. **Analyst Confidence**: The reaffirmation of the "Buy" rating by HC Wainwright and the absence of any "Sell" ratings from analysts for OKYO Pharma indicate a general consensus among analysts of the stock's potential value.
4. **Market Performance**: OKYO Pharma's stock performance has shown volatility, with a beta of -0.04, meaning its price is 104% less volatile than the S&P 500. This could be seen as a positive attribute for investors looking for stability, contributing to the "Strong Buy" sentiment.

These factors combined suggest that analysts have a positive outlook on OKYO Pharma, leading to a "Strong Buy" consensus rating.